PALVELLA THERAPEUTICS, INC. (PVLA) Stock Profile — Insider Trades & Financials

Net Income-$12.7M

EPS$-2.63

Market Cap$1.8B

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Wesley Kaupinen

CEO & Executive Director

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania

Founded: 2015
Employees: 14
Headquarters: Wayne, Pennsylvania, United States

⚡

Core Efficiency

ROE?

-45.43%

ROA?

-21.35%

D/E Ratio?

1.13

📊

Profitability Ratios

Current Ratio?

5.20

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Aug 24, 2026 (in 137 days)

Annual Report (10-K) — Based on filing pattern

Aug 24, 2026

Predicted10-K

Mar 31, 2026

10-KQ4 20256d after period end

Nov 12, 2025

10-QQ3 202511d after period end

Aug 14, 2025

10-QQ2 20256d after period end

May 15, 2025

10-QQ1 20256d after period end

Mar 31, 2025

10-KQ4 20246d after period end

Nov 13, 2024

10-QQ3 20240d after period end

Aug 14, 2024

10-QQ2 20246d after period end

May 15, 2024

10-QQ1 20246d after period end

Loading company sections...

PALVELLA THERAPEUTICS, INC.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness